Quick Answer
Sigyn Therapeutics, Inc. reported Operating Income of -$2.52 million for fiscal year 2024.
Sigyn Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$2.52M | -2.6% |
| 2023 | -$2.46M | -14.3% |
| 2022 | -$2.15M | -6.9% |
| 2021 | -$2.01M | -119.1% |
| 2020 | -$916.4K | -76.9% |
| 2019 | -$518.0K | +48.4% |
| 2018 | -$1.00M | +50.5% |
| 2017 | -$2.03M | +10.0% |
| 2015 | -$2.25M | -481.4% |
| 2014 | -$387.5K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$386.5K | +52.2% | +17.7% |
| June 30, 2025 | -$469.5K | +22.1% | +14.0% |
| March 31, 2025 | -$546.1K | +13.3% | +32.5% |
| September 30, 2024 | -$808.5K | -25.8% | -34.1% |
| June 30, 2024 | -$602.8K | -5.0% | +4.3% |
| March 31, 2024 | -$630.0K | -20.9% | +2.0% |
| September 30, 2023 | -$642.8K | -20.5% | -12.0% |
| June 30, 2023 | -$574.0K | -7.7% | -10.1% |
- Sigyn Therapeutics, Inc. showed a decrease of -2.6% in Operating Income compared to the prior fiscal year.
- Over the 2014–2024 period, Sigyn Therapeutics, Inc.’s operating income has declined by 550.1% (from -$387.5 thousand to -$2.52 million).
- The most recent figure is from Sigyn Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: